Law360, New York (February 03, 2012, 1:28 PM ET) -- The U.S. Federal Trade Commission (FTC) has recently released two reports relating to the pharmaceutical industry. A significant theme in both reports is a concern that brand-name pharmaceutical companies are using the threat of launching an authorized generic to make deals that delay generic entry.
These reports shine a spotlight on the interplay between authorized generics and pharmaceutical patent settlements, and indicate strong FTC opposition to a practice that has never been found unlawful.
Report on Authorized Generics
On Aug. 31, 2011, the FTC issued its...
Highlighting 'Pay For Delay' Concerns
To view the full article, take a free trial now.
